Understanding molecular and X-ray crystallographic structures of BCR::ABL1 oncoprotein has led to the development of several potent TKIs for the treatment of CML in the clinical [36]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.